Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
Alkermes plc. Logo
Develops medicines for CNS disorders like schizophrenia, bipolar, and sleep disorders.
United States of America ALKS
Allarity Therapeutics, Inc. Logo
Develops personalized cancer drugs using a diagnostic platform to predict patient response.
United States of America ALLR
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX
Allogene Therapeutics, Inc. Logo
Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.
United States of America ALLO
Israel KVSR
Almirall S.A. Logo
A global biopharmaceutical company developing innovative medical solutions for skin health.
Spain ALM
ALNYLAM PHARMACEUTICALS, INC. Logo
Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.
United States of America ALNY

Talk to a Data Expert

Have a question? We'll get back to you promptly.